El IGF-1 LR3 es una variante de acción prolongada del factor de crecimiento similar a la insulina 1, usada en investigación; sin aprobación como medicamento.
IGF-1 LR3 is a recombinantly produced variant of human IGF-1. Two changes define its properties: (1) at position 3, glutamic acid is replaced by arginine; (2) a 13-amino-acid sequence is added at the N-terminus ('Long'). Both modifications drastically reduce affinity for the six IGF-binding proteins (IGFBP-1 to -6) that normally bind native IGF-1 in the blood and regulate its availability at the receptor. As a result, a larger fraction of the molecule is freely available to bind the type-1 IGF receptor (IGF-1R) — the same receptor as native IGF-1. In preclinical models and cell culture, LR3 IGF-1 therefore acts as a more potent agonist than unmodified IGF-1. The downstream signalling pathway (PI3K/Akt and MAPK) is identical to that of IGF-1; the modification changes bioavailability, not the receptor target.
Curva teórica de concentración con una semivida de 21 h. Modelo farmacocinético puro — no es una recomendación de dosis.
Open in PK tool →All forms of exogenous IGF-1 are prohibited at all times, and any substance containing any form of exogenous IGF-1 should be considered prohibited.
Los péptidos vienen como polvo seco. Una vez disuelto en un líquido (reconstitución), esta calculadora responde a una única pregunta: ¿cuánta sustancia hay en un mililitro de solución después?
Solo ciencia, sin ventas. Cancela cuando quieras.
We store your email only for the newsletter. Unsubscribe anytime. Privacy